Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 2/2006

01-02-2006 | Meeting Report

International symposium on tumour escape and its determinants: meeting report

Authors: Kurt S. Zänker, Peter Eckl, Enrico Mihich

Published in: Cancer Immunology, Immunotherapy | Issue 2/2006

Login to get access

Excerpt

The International Symposium on Tumour Escape and its Determinants was held in Salzburg, Austria, October 10–13, 2004, under the joint sponsorship of the International Union Against Cancer (UICC, Geneva), the Fritz-Bender-Foundation (Munich), the Roswell Park Cancer Institute, Buffalo, USA, the Institute of Immunology, University Witten/Herdecke, Germany, the Department of Cell Biology and Genetics, Faculty for Basic Sciences, Paris Lodron University, Salzburg, Austria. …
Metadata
Title
International symposium on tumour escape and its determinants: meeting report
Authors
Kurt S. Zänker
Peter Eckl
Enrico Mihich
Publication date
01-02-2006
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 2/2006
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-005-0034-5

Other articles of this Issue 2/2006

Cancer Immunology, Immunotherapy 2/2006 Go to the issue

Review

DNA vaccines for cancer too

Letter to the Editors

Exciting applications of single chain trimers of MHC-I molecules

Original Article

Maturation of circulating dendritic cells and imbalance of T-cell subsets in patients with squamous cell carcinoma of the head and neck

Original Article

Antiangiogenic chimeric anti-endoglin (CD105) antibody: pharmacokinetics and immunogenicity in nonhuman primates and effects of doxorubicin

Symposium in Writing

T and B cells in B-chronic lymphocytic leukaemia: Faust, Mephistopheles and the pact with the Devil

Symposium in Writing

Immune defects in patients with chronic lymphocytic leukemia
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits